Home/Pipeline/IncellKINE Diagnostic Assays

IncellKINE Diagnostic Assays

Long COVID, ME/CFS, Chronic Lyme Disease (Differentiation)

CommercialActive

Key Facts

Indication
Long COVID, ME/CFS, Chronic Lyme Disease (Differentiation)
Phase
Commercial
Status
Active
Company

About HealthBio AI

HealthBio AI is a clinical-stage biotech company developing an integrated platform of AI-driven diagnostics and therapeutics for chronic inflammatory diseases. The company's core hypothesis centers on immune dysregulation driven by persistent viral proteins, such as the SARS-CoV-2 S1 protein in Long COVID. With an FDA-accepted Phase 2/3 clinical trial for a Long COVID therapeutic and a commercial diagnostic test, HealthBio AI is pursuing a vertically integrated model from diagnosis to treatment management. The company is privately held and appears to be in an early-revenue stage, supported by diagnostic test sales.

View full company profile